| Literature DB >> 30193112 |
Niv Zmora1, Gili Zilberman-Schapira2, Jotham Suez2, Uria Mor2, Mally Dori-Bachash2, Stavros Bashiardes2, Eran Kotler3, Maya Zur2, Dana Regev-Lehavi2, Rotem Ben-Zeev Brik2, Sara Federici2, Yotam Cohen2, Raquel Linevsky2, Daphna Rothschild3, Andreas E Moor4, Shani Ben-Moshe4, Alon Harmelin5, Shalev Itzkovitz4, Nitsan Maharshak6, Oren Shibolet6, Hagit Shapiro2, Meirav Pevsner-Fischer2, Itai Sharon7, Zamir Halpern8, Eran Segal9, Eran Elinav10.
Abstract
Empiric probiotics are commonly consumed by healthy individuals as means of life quality improvement and disease prevention. However, evidence of probiotic gut mucosal colonization efficacy remains sparse and controversial. We metagenomically characterized the murine and human mucosal-associated gastrointestinal microbiome and found it to only partially correlate with stool microbiome. A sequential invasive multi-omics measurement at baseline and during consumption of an 11-strain probiotic combination or placebo demonstrated that probiotics remain viable upon gastrointestinal passage. In colonized, but not germ-free mice, probiotics encountered a marked mucosal colonization resistance. In contrast, humans featured person-, region- and strain-specific mucosal colonization patterns, hallmarked by predictive baseline host and microbiome features, but indistinguishable by probiotics presence in stool. Consequently, probiotics induced a transient, individualized impact on mucosal community structure and gut transcriptome. Collectively, empiric probiotics supplementation may be limited in universally and persistently impacting the gut mucosa, meriting development of new personalized probiotic approaches.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30193112 DOI: 10.1016/j.cell.2018.08.041
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582